HomeNDC LookupIngredientsTestosterone Enanthate › 54436-0275-04
XYOSTED testosterone enanthate 75 mg/.5mL Injection, 4 syringes — NDC 54436-0275-04 package photo

XYOSTED testosterone enanthate 75 mg/.5mL Injection, 4 syringes

by Antares Pharma, Inc. · 4 SYRINGE in 1 CARTON (54436-275-04) / .5 mL in 1 SYRINGE (54436-275-02)
NDC 54436-0275-04
🏷️ FDA NDC (as labeled) 54436-275-04 billing pads the product segment with a zero
This package
Contains4 syringes Cost per mL$316.45 NADAC Per package$632.90 / 2 ml Pack sizes3 compare ↓
Also priced by: Medicaid pays $309.69/unit · Part D plans $319.76/unit — full pricing hub ↓
Rx only Brand On market CIII
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 54436-275-04
Product NDC 54436-275
11-digit billing NDC 54436027504
NCPDP billing unit ML — per mL (volume)
UNII 7Z6522T8N9
Application # NDA209863
SPL Set ID 8a3d204c-be26-49e0-8599-0ac12a272e81
Established class (EPC) Androgen
Mechanism of action Androgen Receptor Agonists
Chemical class Androstanes
DEA schedule CIII
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-11-15
Route SUBCUTANEOUS
Dosage form INJECTION
Substance TESTOSTERONE ENANTHATE
GPI-14 2310003020D530
GPI class Xyosted
GCN Seq No 079085
GCN 45517
HICL code 001401
Ingredient (HICL) Testosterone Enanthate
HIC1 code F
Therapeutic class — broad (HIC1) Male Genital System
HIC2 code F1
Therapeutic class — intermediate (HIC2) Androgens
HIC3 code F1A
Therapeutic class — specific (HIC3) Androgenic Agents
AHFS code 68:08.00.00
AHFS class Androgens
FDB label name XYOSTED 75 MG/0.5 ML AUTO-INJ
FDB brand name Xyosted
Legend status F — Federal legend — prescription drug or device
Why two NDCs? The FDA registers this code as 54436-275-04 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 54436-0275-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Androgen class.

Pharmacologic class Androgen
Drug family (ATC) 3-oxoandrosten (4) derivatives, Androgens and estrogens
How it works Androgen Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerAntares Pharma, Inc.
Application holderANTARES PHARMA INC
FDA applicationNDA209863 (NDA)
Labeler code54436
First marketedNov 2018
DEA scheduleCIII
Product typeHuman Prescription Drug
Portfolio11 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name XYOSTED 75 MG/0.5 ML AUTO-INJ Ingredient Testosterone Enanthate
📗 Our plain-language guide HelloPharmacist
  • This gel is specifically approved for men who have a diagnosed medical condition causing low testosterone — like Klinefelter's syndrome, damage from chemotherapy, or a problem with...
  • What exactly is this medication for — do I really need it just because my testosterone is a little low?
  • Yes — where you apply it matters a lot. Use it only on the upper arms and shoulders, once every morning on clean, dry skin. Don't apply it to your abdomen, genitals, chest, armpits...
  • How do I apply it correctly, and does it matter where I put it on my body?
📖 Read our full Testosterone Topical guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $316.449 $632.90 / 2 ml
Medicaid paysCMS SDUD · 12 mo $309.69 $619.38 / 2 ml
Medicare drug plans payPart D · Q2 2026 $319.76 $639.51 / 2 ml
NADAC price history (per mL) — tap or hover for the price & month
Jul 2021 Oct 2023 May 2026 Aug 2026 $316.847 $262.661
▲ Up 20% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Xyosted 75 mg/.5mLthis 54436-0275-04 Antares 4 syringes $316.449 Availability likely
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2018
First FDA approval
Sep 2018
📍
2026
Currently FDA-listed
8 years listed
🛡️
2036
Latest patent/protection listed
not a guaranteed launch date
🔒No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.

🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Sep 2036. This may affect when a full generic version becomes widely available, but it is not a guaranteed launch date.
📅 FDA approved Sep 28, 2018 RLD RS ⏳ ~10 yr to latest listed protection

Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.

Patents & exclusivity — FDA Orange Book
US 9950125 — method of use (U-2418)
US 9950125 — method of use (U-2418)
US 10912782 — method of use (U-2418)
US 10912782 — method of use (U-2418)
US 10912782 — method of use (U-2418)
US 11844804 — method of use (U-2418)
US 11844804 — method of use (U-2418)
US 11844804 — method of use (U-2418)
US 9950125 — method of use (U-2418)
US 10821072 — method of use (U-2418)
US 10821072 — method of use (U-2418)
US 10821072 — method of use (U-2418)
US 10238662 — method of use (U-2418)
US 10238662 — method of use (U-2418)
US 10238662 — method of use (U-2418)
US 11160751 — method of use (U-2418)
US 11160751 — method of use (U-2418)
US 11160751 — method of use (U-2418)
US 11191908 — drug product
US 11446440 — drug product
US 10478560 — drug product
US 11813435 — drug product
US 11446440 — drug product
US 10357609 — drug product
US 10881798 — drug product
US 8021335 — drug product
US 9533102 — drug product
US 9744302 — drug product
US 8021335 — drug product
US 12629483 — drug product
US 12629483 — drug product
US 9629959 — drug product
US 10357609 — drug product
US 8562564 — drug product
US 10905827 — drug product
US 11446441 — drug product
US 10905827 — drug product
US 11191908 — drug product
US 10279131 — drug product
US 11497753 — drug product
US 11813435 — drug product
US 10905827 — drug product
US 11446441 — drug product
US 11497753 — drug product
US 9744302 — drug product
US 11497753 — drug product
US 9533102 — drug product
US 10881798 — drug product
US 9180259 — drug product
US 9180259 — drug product
US 9180259 — drug product
US 10881798 — drug product
US 9629959 — drug product
US 10279131 — drug product
US 11813435 — drug product
US 9629959 — drug product
US 8562564 — drug product
US 10478560 — drug product
US 10279131 — drug product
US 11191908 — drug product
US 11446440 — drug product
US 9533102 — drug product
US 10478560 — drug product
US 10357609 — drug product
US 12629483 — drug product
US 11446441 — drug product
US 8021335 — drug product
US 9744302 — drug product
US 8562564 — drug product
2018 2020 2022 2024 2026 2028 2030 2032 2034 2036
Today
LOE
Substance patent Formulation patent Method-of-use patent Exclusivity Pediatric +6mo
🏛️FDA exclusivity
FDA-granted marketing protection. It’s separate from patents and may be shorter than patent protection.
🧪Product / substance patents
Patents covering the active ingredient, product, formulation, or related drug features.
🎯Method-of-use patents
Patents covering specific approved uses. These can sometimes be carved out with a “skinny label,” but not always.
🛈 What do these terms mean?
Patent
Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
Substance patent
Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
Formulation (product) patent
Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
Method-of-use patent
A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
Skinny label
A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
Exclusivity
FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
Paragraph IV
A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
RLD / RS
Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
TE / AB rating
FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
LOE (loss of exclusivity)
The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.

Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.

Listed patents (69)
PatentTypeUse codeExpires
US 9950125 ↗ Method of use U-2418 Sep 4, 2036
US 9950125 ↗ Method of use U-2418 Sep 4, 2036
US 10912782 ↗ Method of use U-2418 Feb 19, 2035
US 10912782 ↗ Method of use U-2418 Feb 19, 2035
US 10912782 ↗ Method of use U-2418 Feb 19, 2035
US 11844804 ↗ Method of use U-2418 Jun 4, 2033
US 11844804 ↗ Method of use U-2418 Jun 4, 2033
US 11844804 ↗ Method of use U-2418 Jun 4, 2033
US 9950125 ↗ Method of use U-2418 Sep 4, 2036
US 10821072 ↗ Method of use U-2418 Jun 4, 2033
US 10821072 ↗ Method of use U-2418 Jun 4, 2033
US 10821072 ↗ Method of use U-2418 Jun 4, 2033
US 10238662 ↗ Method of use U-2418 Feb 19, 2035
US 10238662 ↗ Method of use U-2418 Feb 19, 2035
US 10238662 ↗ Method of use U-2418 Feb 19, 2035
US 11160751 ↗ Method of use U-2418 Oct 7, 2034
US 11160751 ↗ Method of use U-2418 Oct 7, 2034
US 11160751 ↗ Method of use U-2418 Oct 7, 2034
US 11191908 ↗ Drug product Oct 18, 2035
US 11446440 ↗ Drug product Aug 21, 2031
US 10478560 ↗ Drug product Jan 24, 2026
US 11813435 ↗ Drug product Feb 25, 2035
US 11446440 ↗ Drug product Aug 21, 2031
US 10357609 ↗ Drug product Aug 21, 2031
US 10881798 ↗ Drug product Feb 11, 2034
US 8021335 ↗ Drug product Oct 4, 2026
US 9533102 ↗ Drug product Jan 24, 2026
US 9744302 ↗ Drug product Nov 19, 2035
US 8021335 ↗ Drug product Oct 4, 2026
US 12629483 ↗ Drug product Aug 7, 2035
US 12629483 ↗ Drug product Aug 7, 2035
US 9629959 ↗ Drug product Jan 24, 2026
US 10357609 ↗ Drug product Aug 21, 2031
US 8562564 ↗ Drug product Jan 24, 2026
US 10905827 ↗ Drug product Aug 21, 2031
US 11446441 ↗ Drug product Jan 24, 2026
US 10905827 ↗ Drug product Aug 21, 2031
US 11191908 ↗ Drug product Oct 18, 2035
US 10279131 ↗ Drug product Jul 31, 2031
US 11497753 ↗ Drug product Mar 19, 2030
US 11813435 ↗ Drug product Feb 25, 2035
US 10905827 ↗ Drug product Aug 21, 2031
US 11446441 ↗ Drug product Jan 24, 2026
US 11497753 ↗ Drug product Mar 19, 2030
US 9744302 ↗ Drug product Nov 19, 2035
US 11497753 ↗ Drug product Mar 19, 2030
US 9533102 ↗ Drug product Jan 24, 2026
US 10881798 ↗ Drug product Feb 11, 2034
US 9180259 ↗ Drug product Jan 24, 2026
US 9180259 ↗ Drug product Jan 24, 2026
US 9180259 ↗ Drug product Jan 24, 2026
US 10881798 ↗ Drug product Feb 11, 2034
US 9629959 ↗ Drug product Jan 24, 2026
US 10279131 ↗ Drug product Jul 31, 2031
US 11813435 ↗ Drug product Feb 25, 2035
US 9629959 ↗ Drug product Jan 24, 2026
US 8562564 ↗ Drug product Jan 24, 2026
US 10478560 ↗ Drug product Jan 24, 2026
US 10279131 ↗ Drug product Jul 31, 2031
US 11191908 ↗ Drug product Oct 18, 2035
US 11446440 ↗ Drug product Aug 21, 2031
US 9533102 ↗ Drug product Jan 24, 2026
US 10478560 ↗ Drug product Jan 24, 2026
US 10357609 ↗ Drug product Aug 21, 2031
US 12629483 ↗ Drug product Aug 7, 2035
US 11446441 ↗ Drug product Jan 24, 2026
US 8021335 ↗ Drug product Oct 4, 2026
US 9744302 ↗ Drug product Nov 19, 2035
US 8562564 ↗ Drug product Jan 24, 2026
Common questions
Is there a generic version of XYOSTED 75 MG/0.5 ML AUTO-INJ?
No FDA-approved generic equivalent is currently listed in the FDA Orange Book for XYOSTED 75 MG/0.5 ML AUTO-INJ. Based on the patents and exclusivity currently listed, the Orange Book estimate is that full-label generic entry may be delayed until Sep 2036 — an estimate, not a guaranteed launch date.
The FDA approved a generic — why can’t I get it at my pharmacy yet?
FDA approval and pharmacy availability are two different things. The FDA can approve a generic years before it actually reaches pharmacies, because the brand company may still hold patents or have a settlement that delays the launch. A manufacturer also has to choose to make and sell it, and have supply ready. So a drug can be “FDA-approved generic exists” and still be brand-only at the counter today.
Why do different websites show different generic release dates?
Generic availability is not based on one single date. Some sources use the first exclusivity expiration, some use the last product patent, and others use the latest method-of-use patent. Patent challenges, settlements, licenses, and label carve-outs can also change the real-world launch date. This page shows the underlying Orange Book dates so you can see why estimates may differ.
What does “FDA listed” mean?
It means the product appears in the FDA’s official NDC directory. That’s a good sign a product exists and is intended for the U.S. market, but on its own it does not confirm a pharmacy can fill it today. Where we have recent retail pricing data (NADAC) for a product, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Orange Book for a patent or exclusivity on the brand product. It can affect when a full generic version becomes widely available — but it is not a guaranteed generic launch date. Generics sometimes arrive earlier (through a settlement or patent challenge) or later (a manufacturer still has to make and sell one).
What does “current Orange Book estimate” mean?
It means we are using the latest patent and exclusivity dates currently listed in the FDA Orange Book. It is not a guaranteed launch date.
Can a generic come out before the last patent expires?
Sometimes. A generic company may challenge a patent, settle with the brand manufacturer, receive a license, or obtain approval with a narrower label that avoids a patented use. In other cases, the last listed protection may delay full-label generic competition.
Can a generic come out after the listed dates?
Yes. Even after patents or exclusivity expire, a generic still needs FDA approval and a manufacturer must choose to market it. Supply, litigation, business decisions, or regulatory issues can delay actual availability.
What is the difference between patents and exclusivity?
Patents are legal protections usually issued by the U.S. Patent and Trademark Office. FDA exclusivity is marketing protection granted by the FDA. They are separate, and either one can affect generic timing.
Why are there multiple patent dates?
One drug can have several patents covering different things: the active ingredient, a formulation, a manufacturing process, or a specific approved use. That is why a page may show several expiration dates instead of one simple generic date.
Built from FDA Orange Book patent and exclusivity data. Dates are refreshed from public FDA data when available; the marker is max(latest patent expiry, latest exclusivity expiry). Paragraph-IV settlements and first-filer 180-day exclusivity can shift the real date; a method-of-use patent may allow an earlier skinny-label generic for non-protected indications. Generic launch timing is an estimate, not a guarantee.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 54436-0275-04, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
8.1K
Units reimbursed last 4 qtrs
17.8K
Gross reimbursed last 4 qtrs
$5.52M
Avg / prescription
$678.73
Avg / unit
$309.69
Latest quarter Q4 2025
2KRx
Medicaid pays / mL
$309.69
gross reimbursed
vs
NADAC / mL
$316.45
acquisition cost
=
Spread
−$6.7601
-2% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
55% FFS 45% MCO
Fee-for-service · 4,466 Rx Managed care · 3,674 Rx
State Medicaid map
Alaska: 24 units · 3.3 per 100k residents AK Maine: 24 units · 1.7 per 100k residents ME Washington: 380 units · 4.9 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 188 units · 3.3 per 100k residents MN Wisconsin: 118 units · 2.0 per 100k residents WI Michigan: 404 units · 4.0 per 100k residents MI New York: 3,610 units · 18.4 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 106 units · 2.5 per 100k residents OR Nevada: 286 units · 9.0 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 190 units · 1.5 per 100k residents IL Indiana: 562 units · 8.2 per 100k residents IN Ohio: 581 units · 4.9 per 100k residents OH Pennsylvania: 776 units · 6.0 per 100k residents PA New Jersey: 82 units · 0.9 per 100k residents NJ Massachusetts: 400 units · 5.7 per 100k residents MA California: 3,546 units · 9.1 per 100k residents CA Utah: no data reported UT Colorado: 418 units · 7.1 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 1,467 units · 32.4 per 100k residents KY West Virginia: no data reported WV Virginia: 358 units · 4.1 per 100k residents VA Maryland: 258 units · 4.2 per 100k residents MD Connecticut: 2,094 units · 57.9 per 100k residents CT Rhode Island: 410 units · 37.4 per 100k residents RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 108 units · 1.5 per 100k residents TN North Carolina: 694 units · 6.4 per 100k residents NC South Carolina: 106 units · 2.0 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 652 units · 14.3 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
0.957.9
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Connecticut 57.9 /100k
2 Rhode Island 37.4 /100k
3 Kentucky 32.4 /100k
4 New York 18.4 /100k
5 Louisiana 14.3 /100k
6 California 9.1 /100k
7 Nevada 9.0 /100k
8 Indiana 8.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
4 syringes this page54436-0275-04 8,140 Rx · $5,524,850
1 syringe54436-0275-01 No Medicaid data
1 syringe54436-0275-05 No Medicaid data
Drug total (last 4 qtrs): 8,140 Rx · 17,840 units · $5,524,850 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Xyosted — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Xyosted. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$9.55M
Claims incl. refills
11.8K
Beneficiaries
6K
Spend / beneficiary
$1,585.26
Spend / claim
$812.39
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
54436-0275-01 1 SYRINGE in 1 CARTON (54436-275-01) / .5 mL in 1 SYRINGE (54436-275-03) 2018-11-15 Active
54436-0275-04 You're viewing this 4 SYRINGE in 1 CARTON (54436-275-04) / .5 mL in 1 SYRINGE (54436-275-02) $316.45 / mL $632.90 2018-11-15 Active
54436-0275-05 1 SYRINGE in 1 CARTON (54436-275-05) / .5 mL in 1 SYRINGE (54436-275-02) 2024-01-08 Active

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in NDC 54436-0275-04?
NDC 54436-0275-04 contains 4 syringes — 4 syringe in 1 carton / .5 ml in 1 syringe.
What is the difference between NDC 54436-0275-04 and NDC 54436-0275-01?
Both are XYOSTED testosterone enanthate 75 mg/.5mL Injection — the drug itself is identical. NDC 54436-0275-04 is the 4 syringes package, while NDC 54436-0275-01 is the 1 syringe package.
What NDC number is used to bill for this package of XYOSTED testosterone enanthate 75 mg/.5mL Injection?
Bill NDC 54436-0275-04 — the 11-digit billing format is 54436027504. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ~1 min read

1 INDICATIONS AND USAGE XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.

Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established.

Safety and efficacy of XYOSTED in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Limitations of Use: Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established ( 1 ).

Safety and efficacy of XYOSTED in males less than 18 years old have not been established ( 1 , 8.4 ).

⏱️ Dosage and Administration ~2 min read

2 DOSAGE AND ADMINISTRATION Prior to initiating XYOSTED : confirm the diagnosis of hypogonadism by ensuring that serum testosterone has been measured in the morning on at least two separate days and that these concentrations are below the normal range ( 2.1 ). Starting dose: 75 mg subcutaneously in the abdominal region once weekly. Avoid intramuscular and intravascular administration ( 2.2 , 2.3 ).

Dose Adjustment: Based upon total testosterone trough concentrations (measured 7 days after most recent dose) obtained following 6 weeks of dosing and periodically thereafter ( 2.2 ). Discard unused portion ( 2.3 )

2.1Confirmation of Hypogonadism Before Initiation of XYOSTED Prior to initiating XYOSTED, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.

2.2Starting Dose and Dose Adjustment The starting dose of XYOSTED is 75 mg, administered subcutaneously in the abdominal region once a week. Dose adjustment Measure total testosterone trough concentrations (measured 7 days after the most recent dose) following 6 weeks of dosing, following 6 weeks after dose adjustment, and periodically while on treatment with XYOSTED. A trough concentration between 350 ng/dL and 650 ng/dL generally provides testosterone exposures in the normal range during the entire dosing interval.

Decrease the dose by 25 mg if the total testosterone trough concentration (C trough ) is ≥650 ng/dL. Increase the dose by 25 mg if the total testosterone C trough is <350 ng/dL. Maintain the same dose if the total testosterone C trough is ≥350 ng/dL and <650 ng/dL.

2.3Important Administration Instructions XYOSTED is for subcutaneous injection in the abdominal region only. Avoid intramuscular or intravascular injection. Instruct patients on the proper use of XYOSTED and direct them to use the proper injection site.

Refer to the Instructions for Use for proper use of XYOSTED. Visually inspect XYOSTED for particulate matter and discoloration prior to administration. Do not use if the liquid is cloudy or if visible particles are present.

Do not use XYOSTED if the seal is broken. Discard unused portion.

💊 Dosage Forms and Strengths 90 words

3 DOSAGE FORMS AND STRENGTHS XYOSTED injection is available as 0.5 mL of a sterile, preservative-free and nonpyrogenic, clear, colorless to yellow solution containing testosterone enanthate. It is supplied in a single-dose syringe assembled in an autoinjector for subcutaneous administration. XYOSTED is available in three dosage strengths: 50 mg/0.5 mL 75 mg/0.5 mL 100 mg/0.5 mL XYOSTED (testosterone enanthate) Injection is supplied as 0.5 mL of sterile solution in a single-dose autoinjector for subcutaneous administration in three strengths ( 3 ): 50 mg/0.5 mL 75 mg/0.5 mL 100 mg/0.5 mL

Contraindications 124 words

4 CONTRAINDICATIONS XYOSTED is contraindicated in: Men with carcinoma of the breast or known or suspected carcinoma of the prostate [see Warnings and Precautions ( 5.4 )] . Women who are pregnant. Testosterone can cause virilization of the female fetus when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] .

Men with known hypersensitivity to XYOSTED or any of its ingredients (testosterone enanthate and sesame oil). Men with carcinoma of the breast or known or suspected carcinoma of the prostate ( 4 , 5.4 ). Women who are pregnant ( 4 , 8.1 ).

Testosterone may cause fetal harm ( 4 , 5.7 , 8.1 , and 8.2 ). Known hypersensitivity to XYOSTED or its ingredients ( 4 ).

⚠️ Warnings and Cautions ~3 min read

5 WARNINGS AND PRECAUTIONS Polycythemia: Monitor hematocrit approximately every 3 months to detect increased red blood cell mass and polycythemia ( 5.1 ). Venous thromboembolism (VTE): VTE including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported in patients using testosterone products. Evaluate patients with signs or symptoms consistent with DVT or PE ( 5.2 ).

Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer: Monitor patients with BPH for worsening signs and symptoms of BPH ( 5.3 ). Blood Pressure Increases: Testosterone can increase blood pressure, which can increase cardiovascular risk over time. Measure blood pressure periodically.

Not recommended for use in men with uncontrolled hypertension ( 5.4 ). Abuse of Testosterone: Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids ( 5.5 ). Potential for Adverse Effects on Spermatogenesis: Exogenous administration of androgens may lead to azoospermia ( 5.7 ).

Edema: Edema with or without congestive heart failure may be a complication in patients with preexisting cardiac, renal, or hepatic disease ( 5.9 ). Sleep apnea: Sleep apnea may occur in those with risk factors ( 5.11 ). Monitor prostatic specific antigen (PSA) and lipid concentrations periodically ( 5.3 , 5.12 ).

Depression and suicidal ideation and behavior, including completed suicide, have occurred during clinical trials in patients treated with XYOSTED ( 5.15 ).

5.1Polycythemia Increases in hematocrit reflective of increases in red blood cell mass may require discontinuation of XYOSTED. Check that hematocrit is not elevated prior to initiating XYOSTED. Evaluate hematocrit approximately every 3 months while the patient is on XYOSTED.

If hematocrit becomes elevated, stop XYOSTED until the hematocrit decreases to an acceptable level. If XYOSTED is restarted and again causes hematocrit to become elevated, stop XYOSTED permanently. An increase in red blood cell mass may increase the risk of thromboembolic events.

5.2Venous Thromboembolism There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products, such as XYOSTED. In the Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy Response in hypogonadal men (TRAVERSE) Study, a randomized, double-blind, placebo-controlled, cardiovascular (CV) outcomes study, compared to placebo, topical testosterone gel was associated with a numerically higher incidence of VTE (1.7% vs 1.2%) which included DVT (0.6% vs 0.5%) and PE events (0.9% vs 0.5%) [see Adverse Reactions ( 6.1 )] .

Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with XYOSTED and initiate appropriate workup and management.

5.3Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer Patients with BPH treated with androgens are at an increased risk of worsening of signs and symptoms of BPH. Monitor patients with BPH for worsening signs and symptoms. Patients treated with androgens may be at an increased risk for prostate cancer.

Evaluate patients for prostate cancer prior to initiating and during treatment with androgens [see Contraindications ( 4 )] .

5.4Blood Pressure Increases XYOSTED can increase blood pressure. Ambulatory blood pressure monitoring (ABPM) demonstrated XYOSTED increased systolic/diastolic BP by an average of 3.9/1.5 mm Hg from baseline after 12 weeks of treatment in clinical trials [see Adverse Reactions ( 6.1 )]. In patients with hypertension on antihypertensive therapy, XYOSTED increased the mean systolic/diastolic BP by 3.9/1.3 mm Hg from baseline. The CV risk a…

🤒 Adverse Reactions ~3 min read

6 ADVERSE REACTIONS The most commonly reported adverse reactions (>5%) were: hematocrit increased, hypertension, PSA increased, injection site bruising, and headache. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Antares at 1-844-XYOSTED (1-844-996-7833) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of XYOSTED was evaluated in 2 clinical studies in a total of 283 men who received weekly subcutaneous doses for up to one year. All patients were started on 75 mg weekly, then the dose was titrated to 50 mg or 100 mg weekly, as needed, to achieve pre-dose total testosterone concentrations of ≥350 ng/dL and <650 ng/dL.

Table 1 summarizes adverse reactions (≥2%) reported in a one-year study with XYOSTED. Table 1. Number (%) of Patients with Adverse Reactions ≥2% in a 1 Year study with XYOSTED Preferred Term Overall (N=150) n (%) Hematocrit increased 21 (14.0) Hypertension 19 (12.7) Prostatic specific antigen (PSA) increased 18 (12.0) Injection site bruising 10 (6.7) Headache 8 (5.3) Back pain 5 (3.3) Blood creatine phosphokinase increased 5 (3.3) Injection site hemorrhage 5 (3.3) Acne 4 (2.7) Blood testosterone increased 4 (2.7) Cough 4 (2.7) Edema peripheral 4 (2.7) Injection site erythema 4 (2.7) Prostatitis 4 (2.7) Urinary tract infection 4 (2.7) Abdominal pain 3 (2.0) Arthralgia 3 (2.0) Fatigue 3 (2.0) Hematuria 3 (2.0) Polycythemia 3 (2.0) Sleep apnea syndrome 3 (2.0) Note: Includes events that started on or after the first dosing, or existed prior to the first dose and worsened in severity or relatedness after dosing.

Percentage was calculated using the number of patients in the column heading as the denominator. Table 2 summarizes the adverse reactions (≥2%) reported in a 6-month study with XYOSTED. Table 2.

Number (%) of Patients with Adverse Reactions ≥2% in a 6-Month Study with XYOSTED Preferred Term Overall (N = 133) n (%) Hematocrit increased 11 (8.3) Injection site hemorrhage 8 (6.0) Blood creatine phosphokinase increased 5 (3.8) Injection site bruising 5 (3.8) Prostatitis 4 (3.0) Prostatic specific antigen (PSA) increased 4 (3.0) Urinary tract infection 4 (3.0) Fatigue 3 (2.3) Hypertension 3 (2.3) Insomnia 3 (2.3) Nausea 3 (2.3) Note: Includes events that started on or after the first dosing, or existed prior to the first dose and worsened in severity or relatedness after dosing.

Percentage was calculated using the number of patients in the column heading as the denominator. BP Increases in the 6-Month Clinical Study In the 6-month clinical study, 24-hour ambulatory blood pressure monitoring (ABPM) was conducted in 133 patients, 113 of whom completed the study. ABPM was conducted at 3 distinct 24-hour time periods: at Baseline and following 6 and 12 weeks of XYOSTED therapy.

A total of 62 patients had acceptable ABPM recordings at baseline and Week 12. In that group, the mean change in systolic and diastolic BP from baseline to Week 12 was + 3.9 mm Hg (95% CI 1.4-6.4) and + 1.5 mm Hg (95% CI 0.4-2.6), respectively. In patients with a history of hypertension who were receiving antihypertensive therapy, the mean ABPM systolic and diastolic BP increased by +3.9 mm Hg [95% CI 0.19-7.7] and +1.3 mm Hg [95% CI -0.37-3.0], respectively [n=33]).

In patients with no history of hypertension, the mean ABPM systolic and diastolic blood pressure increased by +4.1 mm Hg [95% CI 0.43-7.8] and +1.9 mm Hg [95% CI 0.055-3.7], respectively [n=28]). 10% of XYOSTED-treated patients were either started on antihypertensive medications or required changes to their antihypertensive medication regimen during the 1-year study. A total of 3 patients were reported to have an adverse reaction of hypertension (2 patients with hyperten…

🔄 Drug Interactions ~1 min read

7 DRUG INTERACTIONS Androgens may decrease blood glucose, and therefore may decrease insulin requirements in diabetic patients ( 7.1 ). Changes in anticoagulant activity may be seen with androgens. More frequent monitoring of international normalized ratio (INR) and prothrombin time is recommended in patients taking warfarin ( 7.2 ).

Use of testosterone with corticosteroids may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease ( 7.3 ). Concomitant administration of medications that are known to increase BP with XYOSTED may lead to additional increases in BP ( 7.4 ).

7.1Insulin Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of anti-diabetic medication.

7.2Oral Anticoagulants Changes in anticoagulant activity may be seen with androgens, therefore more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy.

7.3Corticosteroids The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring, particularly in patients with cardiac, renal or hepatic disease.

7.4Medications that May Also Increase Blood Pressure Some prescription medications and nonprescription analgesic and cold medications contain drugs known to increase blood pressure. Concomitant administration of these medications with XYOSTED may lead to additional increases in blood pressure.

👥 Use in Specific Populations ~2 min read

8 USE IN SPECIFIC POPULATIONS Geriatric Patients: There are insufficient long-term safety data to assess the potential risks of cardiovascular disease and prostate cancer ( 8.5 ).

8.1Pregnancy Risk Summary XYOSTED is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action [see Contraindications ( 4 ) and Clinical Pharmacology ( 12.1 )] . Exposure of a female fetus to androgens may result in varying degrees of virilization.

In animal developmental studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in female and male offspring. These studies did not meet current standards for nonclinical development toxicity studies. Data Animal Data In developmental studies conducted in rats, rabbits, pigs, sheep and rhesus monkeys, pregnant animals received intramuscular injection of testosterone during the period of organogenesis.

Testosterone treatment at doses that were comparable to those used for testosterone replacement therapy resulted in structural impairments in both female and male offspring. Structural impairments observed in females included increased ano-genital distance, phallus development, empty scrotum, no external vagina, intrauterine growth retardation, reduced ovarian reserve, and increased ovarian follicular recruitment. Structural impairments seen in male offspring included increased testicular weight, larger seminal tubular lumen diameter, and higher frequency of occluded tubule lumen.

Increased pituitary weight was seen in both sexes. Testosterone exposure in utero also resulted in hormonal and behavioral changes in offspring. Hypertension was observed in pregnant females and offspring in rats exposed to doses approximately twice those used for testosterone replacement therapy.

8.2Lactation Risk Summary XYOSTED is not indicated for use in females.

8.3Females and Males of Reproductive Potential Infertility During treatment with large doses of exogenous androgens, including XYOSTED, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis [ see Warnings and Precautions ( 5.8 ) ] . Reduced fertility is observed in some men taking testosterone replacement therapy. The impact on fertility may be irreversible.

8.4Pediatric Use Safety and effectiveness of XYOSTED in pediatric patients less than 18 years old have not been established. Improper use may result in acceleration of bone age and premature closure of epiphyses.

8.5Geriatric Use There have not been sufficient numbers of geriatric patients in controlled clinical studies with XYOSTED to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. Of the 283 patients enrolled in the 6-month and one-year efficacy and safety clinical study utilizing XYOSTED, 49 (17%) were over 65 years of age. Additionally, there are insufficient long-term safety data in geriatric patients to assess the potentially increased risk of cardiovascular disease and prostate cancer.

Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of BPH [see Warnings and Precautions ( 5.4 )].

🤰 Pregnancy ~1 min read

8.1Pregnancy Risk Summary XYOSTED is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action [see Contraindications ( 4 ) and Clinical Pharmacology ( 12.1 )] . Exposure of a female fetus to androgens may result in varying degrees of virilization.

In animal developmental studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in female and male offspring. These studies did not meet current standards for nonclinical development toxicity studies. Data Animal Data In developmental studies conducted in rats, rabbits, pigs, sheep and rhesus monkeys, pregnant animals received intramuscular injection of testosterone during the period of organogenesis.

Testosterone treatment at doses that were comparable to those used for testosterone replacement therapy resulted in structural impairments in both female and male offspring. Structural impairments observed in females included increased ano-genital distance, phallus development, empty scrotum, no external vagina, intrauterine growth retardation, reduced ovarian reserve, and increased ovarian follicular recruitment. Structural impairments seen in male offspring included increased testicular weight, larger seminal tubular lumen diameter, and higher frequency of occluded tubule lumen.

Increased pituitary weight was seen in both sexes. Testosterone exposure in utero also resulted in hormonal and behavioral changes in offspring. Hypertension was observed in pregnant females and offspring in rats exposed to doses approximately twice those used for testosterone replacement therapy.

🧒 Pediatric Use 34 words

8.4Pediatric Use Safety and effectiveness of XYOSTED in pediatric patients less than 18 years old have not been established. Improper use may result in acceleration of bone age and premature closure of epiphyses.

🧓 Geriatric Use 107 words

8.5Geriatric Use There have not been sufficient numbers of geriatric patients in controlled clinical studies with XYOSTED to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. Of the 283 patients enrolled in the 6-month and one-year efficacy and safety clinical study utilizing XYOSTED, 49 (17%) were over 65 years of age. Additionally, there are insufficient long-term safety data in geriatric patients to assess the potentially increased risk of cardiovascular disease and prostate cancer.

Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of BPH [see Warnings and Precautions ( 5.4 )].

🆘 Overdosage 63 words

10 OVERDOSAGE There have been no reports of overdosage in the XYOSTED clinical trials. There is a single report of acute overdosage with use of an approved injectable testosterone product. This subject had serum testosterone concentrations of up to 11,400 ng/dL, which were implicated in a cerebrovascular accident. Treatment of overdosage consists of discontinuation of XYOSTED together with appropriate symptomatic and supportive care.

🧬 Clinical Pharmacology ~2 min read

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Endogenous androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution.

Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two main etiologies. Primary hypogonadism is caused by defects of the gonads, such as Klinefelter’s syndrome or Leydig cell aplasia, whereas secondary hypogonadism is the failure of the hypothalamus (or pituitary) to produce sufficient gonadotropins (FSH, LH).

12.2Pharmacodynamics No specific pharmacodynamic studies were conducted using XYOSTED.

12.3Pharmacokinetics Absorption and Bioavailability XYOSTED delivers physiologic amounts of testosterone, producing circulating testosterone concentrations that approximate normal concentrations (300-1100 ng/dL) seen in healthy men. Following weekly subcutaneous injection of XYOSTED for 12 weeks, serum testosterone concentrations reached a maximum after a median of 11.9 hours post-dose (range: 5.8-168.7 hours) then slowly declined (Figure 1). In this study, the starting dose of XYOSTED was 75 mg weekly then the XYOSTED dose was adjusted based upon total testosterone trough concentrations obtained following 6 weeks of dosing [see Dosage and Administration ( 2.2 )] .

Steady state serum testosterone concentration was achieved by Week 6. Figure 1. Mean (±SD) of Total Testosterone (TT) Concentration (ng/dL) Following Weekly Administration of XYOSTED for 12 Weeks (N=137) At Week 12, total testosterone concentrations were measured before and at specified times up to 168 hours after XYOSTED administration then analyzed for pharmacokinetic (PK) parameters (Table 3).

Table 3. Arithmetic Mean (SD) and Range for Total Testosterone Pharmacokinetic Parameters at Week 12 Following Weekly Administration of 50 mg, 75 mg, or 100 mg XYOSTED (N=137) C avg (0-168 hr) (ng/dL) C max (ng/dL) T max (hr) a C min (ng/dL) AUC (0-168 hr) (ng·hr/dL) Mean (SD) 553 (127) 790 (215) 11.9 436 (109) 92,955 (21,385) Min - Max 276 - 1036 389 - 1410 6 - 168 166 - 788 46432 - 173,987 a Reported as median Distribution Circulating testosterone is primarily bound in serum to sex hormone-binding globulin (SHBG) and albumin.

Approximately 40% of testosterone in plasma is bound to SHBG, 2% remains unbound (free), and the rest is loosely bound to albumin and other proteins. Elimination Metabolism Testosterone enanthate is metabolized to testosterone via ester cleavage of the enanthate group. The mean (SD) maximum concentration of testosterone enanthate was 169 (68) ng/dL at Week 12 following weekly administration of XYOSTED.

Testosterone is metabolized to various 17-keto steroids through two different pathways. The major active metabolites of testosterone are estradiol and dihydrotestosterone (DHT). At pre-dose of Week 12 treatment, the mean DHT/testosterone ratio was 0.07 which was within the normal range.

Excretion About 90% of a testosterone dose given intramuscularly is excreted in the urine as glucuronic and sulfuric acid-conjugates of testosterone or as metabolites. About 6% of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver.

Figure 1

🧬 Mechanism of Action 122 words

12.1Mechanism of Action Endogenous androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution.

Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two main etiologies. Primary hypogonadism is caused by defects of the gonads, such as Klinefelter’s syndrome or Leydig cell aplasia, whereas secondary hypogonadism is the failure of the hypothalamus (or pituitary) to produce sufficient gonadotropins (FSH, LH).

📦 How Supplied / Storage and Handling ~2 min read

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1How Supplied XYOSTED (testosterone enanthate) injection is provided as 0.5 mL of a sterile, preservative-free, and nonpyrogenic colorless to pale yellow solution in a single-dose syringe pre-assembled in an autoinjector for a single subcutaneous administration. XYOSTED is packaged in cartons containing four (4) or one (1) autoinjectors. XYOSTED is available in the following strengths and configurations.

XYOSTED (testosterone enanthate) injection, USP, 50 mg/0.5 mL Carton of 4 autoinjectors NDC 54436-250-04 Autoinjector NDC 54436-250-02 XYOSTED (testosterone enanthate) injection, USP, 75 mg/0.5 mL Carton of 4 autoinjectors NDC 54436-275-04 Carton of 1 autoinjector NDC 54436-275-05 Autoinjector NDC 54436-275-02 XYOSTED (testosterone enanthate) injection, USP, 100 mg/0.5 mL Carton of 4 autoinjectors NDC 54436-200-04 Carton of 1 autoinjector NDC 54436-200-05 Autoinjector NDC 54436-200-02 Before use, each autoinjector should be visually inspected.

XYOSTED should be clear to light yellow in color and free of visible particles. Do not use if the liquid is cloudy or if visible particles are present. You may notice an air bubble, this is normal.

16.2Storage and Handling Do Not refrigerate or freeze. Use at room temperature. Store at controlled room temperature, 20°C to 25°C (68°F - 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light (keep in carton until time of use).

16.1How Supplied XYOSTED (testosterone enanthate) injection is provided as 0.5 mL of a sterile, preservative-free, and nonpyrogenic colorless to pale yellow solution in a single-dose syringe pre-assembled in an autoinjector for a single subcutaneous administration. XYOSTED is packaged in cartons containing four (4) or one (1) autoinjectors. XYOSTED is available in the following strengths and configurations.

XYOSTED (testosterone enanthate) injection, USP, 50 mg/0.5 mL Carton of 4 autoinjectors NDC 54436-250-04 Autoinjector NDC 54436-250-02 XYOSTED (testosterone enanthate) injection, USP, 75 mg/0.5 mL Carton of 4 autoinjectors NDC 54436-275-04 Carton of 1 autoinjector NDC 54436-275-05 Autoinjector NDC 54436-275-02 XYOSTED (testosterone enanthate) injection, USP, 100 mg/0.5 mL Carton of 4 autoinjectors NDC 54436-200-04 Carton of 1 autoinjector NDC 54436-200-05 Autoinjector NDC 54436-200-02 Before use, each autoinjector should be visually inspected.

XYOSTED should be clear to light yellow in color and free of visible particles. Do not use if the liquid is cloudy or if visible particles are present. You may notice an air bubble, this is normal.

📦 Storage and Handling 43 words

16.2Storage and Handling Do Not refrigerate or freeze. Use at room temperature. Store at controlled room temperature, 20°C to 25°C (68°F - 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light (keep in carton until time of use).

📋 Description 126 words

11 DESCRIPTION XYOSTED (testosterone enanthate) injection contains testosterone enanthate, an ester derivative of an endogenous androgen, testosterone. Testosterone enanthate is a white to creamy white crystalline powder described by the chemical name (17β)-17-[(1-Oxoheptyl) oxy]-androst-4-en-3-one. Testosterone enanthate has the molecular formula C 26 H 40 O 3 , the molecular weight 400.59, and the molecular structure with the chemical formula: XYOSTED (testosterone enanthate) injection is a sterile, preservative-free, and nonpyrogenic colorless to pale yellow solution supplied in a single-dose syringe assembled in a pressure-assisted autoinjector for subcutaneous administration.

Each XYOSTED autoinjector contains 50 mg, 75 mg, or 100 mg of testosterone in sesame oil to form 0.5 mL solution providing three product strengths of 50 mg/0.5 mL, 75 mg/0.5 mL, and 100 mg/0.5 mL. Testosterone enanthate structure

💬 Information for Patients ~1 min read

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide and Instructions for Use ). Venous Thromboembolism Inform patients that XYOSTED can cause venous thromboembolism. Advise patients of the signs and symptoms of venous thromboembolism, which may include the following: lower limb pain, edema, or erythema; and dyspnea or chest pain.

Advise patients to promptly report the signs and symptoms of venous thromboembolism, discontinue use of XYOSTED, and seek urgent medical care. Increased Blood Pressure and Risk for Major Adverse Cardiovascular Events (MACE) Inform patients that XYOSTED can increase BP which can increase cardiovascular risk over time. Instruct patients about the importance of monitoring BP periodically while on XYOSTED.

If BP increases while on XYOSTED, antihypertensive medications may need to be started, added, or adjusted to control BP, or XYOSTED may need to be discontinued. Other Adverse Reactions Inform patients that treatment with androgens may lead to adverse reactions which include: Changes in urinary habits related to effects on prostate size, such as increased urination at night, hesitancy, urinary frequency, urinary urgency, having a urine accident, or being unable to pass urine or weak urine flow. Breathing disturbances that may reflect obstructive sleep apnea, including those associated with sleep or excessive daytime sleepiness.

Too frequent or persistent erections of the penis. Ankle swelling that may reflect peripheral edema. Red blood cell count increase, PSA increase, injection site bruising, injection site bleeding.

Instruct patients to report any changes in their state of health, such as changes in urinary habits, breathing, sleep, and mood, including new onset or worsening of depression, or suicidal ideation. Keep XYOSTED out of the reach of children For more information call: 1-844-XYOSTED (1-844-996-7833) or visit www.XYOSTED.com Manufactured For: Antares Pharma, Inc. Ewing, NJ 08628 XYOSTED and the XYOSTED logo are trademarks of Antares Pharma, Inc.

All rights reserved. ©2025 Antares Pharma, Inc. All rights reserved

💬 Medication Guide ~3 min read

This Medication Guide has been approved by the U.S. Food and Drug Administration. For controlled substances, Antares Pharma, Inc. will provide a one-time replacement medication to the patient if the original product is damaged or is unusable due to unforeseen circumstances.

Issued: 07/2025 MEDICATION GUIDE XYOSTED ® (ZYE-oh-sted) (testosterone enanthate) injection, for subcutaneous use CIII What is XYOSTED? XYOSTED is a prescription medicine that contains testosterone. XYOSTED is used to treat adult men who have low or no testosterone due to certain medical conditions.

It is not known if XYOSTED is safe and effective in children younger than 18 years old. Improper use of XYOSTED may affect bone growth in children. It is not known if XYOSTED is safe or effective to treat men who have low testosterone due to aging.

XYOSTED is a controlled substance (CIII) because it contains testosterone that can be a target for people who abuse prescription medicines. Keep your XYOSTED in a safe place to protect it. Never give your XYOSTED to anyone else, even if they have the same symptoms you have.

Selling or giving away this medicine may harm others and it is against the law. XYOSTED is not meant for use by women. Do not take XYOSTED if you: are a man who has breast cancer. have or might have prostate cancer. are a woman who is pregnant.

XYOSTED may harm your unborn baby. are allergic to XYOSTED or to any ingredients in XYOSTED including testosterone or sesame oil. Before you use XYOSTED, tell your healthcare provider about all your medical conditions, including, if you: have high blood pressure or are being treated for high blood pressure. have heart problems. have high red blood cell count (hematocrit) or high hemoglobin laboratory value. have urinary problems due to an enlarged prostate. have kidney or liver problems. have a history of mental health illness including suicidal thoughts or actions, depression, anxiety or mood disorder. have problems breathing while you sleep (sleep apnea).

Tell your healthcare provider about all the medicines you take, including prescription and non­prescription medicines, vitamins, and herbal supplements. Using XYOSTED with other medicines can affect each other. Especially, tell your healthcare provider if you take: insulin medicines that decrease blood clotting (blood thinners) corticosteroids medicines for pain and cold.

Know the medicines you take. Ask your healthcare provider or pharmacist for a list of all your medicines if you are not sure. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.

How should I use XYOSTED? See the detailed Instructions for Use for information about how to use XYOSTED. Use XYOSTED exactly as your healthcare provider tells you to take it.

Your healthcare provider will show you or your caregiver how to inject XYOSTED. You should not inject XYOSTED until you have been trained on the proper way to use it. What are the possible side effects of XYOSTED?

XYOSTED can cause serious side effects including: Increase in red blood cell count (hematocrit) or hemoglobin. XYOSTED increases red blood cell counts in some patients. High red blood cell counts increase the risk of clots, strokes, and heart attacks.

You may need to stop XYOSTED if your red blood cell count increases. Your healthcare provider should check your red blood cell count and hemoglobin while you use XYOSTED. If you already have an enlarged prostate, your signs and symptoms may get worse while using XYOSTED.

This can include: increased urination at night trouble starting your urine stream having to pass urine many times during the day having an urge that you have to go to the bathroom right away having a urine accident being unable to pass urine or weak urine flow Increased risk of prostate cancer . Your healthcare provider should check you for prostate cancer or any other prostate problems before you start and while you use XYOSTED. Blood clots in the legs or lungs.

Si…

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.